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Anti-tumour activity of flavone acetic acid (NSC 347512) in mice -
influence of immune status
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Summary Flavone acetic acid (FAA) is a synthetic flavonoid with dramatic pre-clinical anti-tumour activity
involving a vascular component in its mechanism but no clinical effects have been seen to date. As FAA also
has immunomodulatory activity, immunological factors might explain differences in activity between mouse
and man. This study examines the influence of host immune status on the anti-tumour activity of FAA. Two
human colon tumour xenografts (COBA, HT-29) fail to respond to FAA in nude mice. The lack of activity of
FAA against HT-29 xenografts cannot be explained on the basis of limited drug bioavailability as achievable
plasma, and tumour levels of FAA are similar to those seen in sensitive murine colon tumours. The immune
status of the host also influences the activity of FAA against two transplantable tumours of the mouse colon.
Both these tumours are highly responsive to FAA in their normal NMRI hosts, but neither tumours exhibited
significant growth delay in thymectomised NMRI or nude hosts. Histological examination of treated tumours
revealed significant areas of haemorrhagic necrosis in all three hosts. These data suggest a clear immunological
component in the mechanism of action of FAA which is separate from the previously described haemorrhagic
necrosis.
Flavone acetic acid (FAA) is a synthetic flavonoid with
interesting pre-clinical activity against a broad spectrum of
murine transplantable solid tumours that are refractory to
conventional cytotoxic agents (Corbett et al., 1986; Plowman
et al., 1986; Bibby et al., 1987b; Bibby et al., 1988a). Despite
these promising pre-clinical observations, FAA has no dem-
onstrable clinical activity (Kerr et al., 1989). Previous in vitro
studies with a variety of tumour cell lines have indicated that
high drug concentrations, or long exposure times, are neces-
sary to achieve direct drug cytotoxicity with FAA (Bibby et
al., 1987; CapolongQ et al., 1987; Schroyens et al., 1987).
These drug profiles are not achieved in mice in vivo suggest-
ing that the anti-tumour effects against subcutaneous mouse
tumours are not the result of a direct cytotoxic mechanism.
Numerous possible mechanisms have been proposed in
order to explain this indirect activity and most of these
suggest the involvement of a critical host component. A
number of studies has demonstrated that FAA has immuno-
modulatory activity (Ching & Baguley, 1987; Hornung et al.,
1988; Wiltrout & Hornung, 1988; Ching & Baguley, 1988).
Earlier studies in this laboratory have demonstrated that the
establishment of a tumour vasculature may be necessary for
the achievement of responses (Bibby et al., 1988b). More
recent studies have shown that anti-tumour activity in sub-
cutaneous tumours is accompanied by vascular shut-down
and a reduction in tumour blood flow (Bibby et al., 1989a;
Evelhoch et al., 1988; Zwi et al., 1989). Further investigations
have shown that following FAA treatment in mice, clotting
times were significantly reduced suggesting that possible in-
travascular coagulation occurs resulting in the vascular occ-
lusion of tumours (Murray et al., 1989). Although inhibition
of tumour blood flow by FAA is an obvious component of
its anti-tumour activity in solid subcutaneous tumours it is
still necessary to establish whether this is the key mechanism
of action. It is certainly an attractive possibility because
systemic tumours in mice which do not develop a capillary
blood vasculature do not respond to FAA (Bibby et al.,
1989b).
The anti-tumour activity of FAA in subcutaneous tumours
is accompanied by histological changes similar to those pro-
duced by tumour necrosis factor (TNF) (Baguley et al.,
1989). TNF has been shown to produce thrombus formation
which may be involved in its anti-tumour activity (Shim-
omura et al., 1988). The histological appearance of sub-
cutaneous tumours treated with FAA is also very similar to
that reported following endotoxin treatment (Parr et al.,
1973). The tumour regression brought about by endotoxin
was thought to be due to vascular damage to the tumour
which permitted access for the immune defence mechanisms
of the host to the tumour and also to activation of macro-
phages present within the tumour. Immunosuppression
interfered with the anti-tumour action of endotoxin in spite
of the fact that haemorrhagic necrosis still occurred. Res-
ponse of human tumour xenografts to FAA appears to be
modest (Giavazzi et al., 1988; Finlay et al., 1988; H. Fiebig
personal communication) and there are certainly no pub-
lished data demonstrating spectacular responses similar to
those achieved in subcutaneous murine tumours.
The aims of this present study are to examine the influence
of FAA on the growth of human colon tumour xenografts
(HT29, COBA) in immune suppressed mice and also to
compare the pharmacokinetics of FAA in nude mice with
previously published mouse data (Bibby et al., 1987b; Bibby
et al., 1988a; Bibby et al., 1989a). To further study the
influence of immune status the investigation also compares
the effects of FAA on mouse adenocarcinomas of the colon
(MAC tumours) in their syngeneic hosts with the effects
achieved in nude and thymectomised hosts.
Materials and methods
Drugs
FAA was supplied as pure compound by the NCI (Bethesda)
for the Milan study and dissolved in 5% sodium bicarbonate.
For the Bradford study, clinically formulated FAA was a gift
from Lyonnaise Industrielle Pharmaceutique (Lyon, France).
Formulated FAA was dissolved in physiological saline.
Cyclophosphamide, 5 Fluorouracil (5FU) and tauromustine
(TCNU) were gifts from the Boehringer Corporation, Lon-
don: Roche, Welwyn Garden City, UK and Pharmacia LEO
Therapeutics AB, Helsingborg, Sweden, respectively. They
were dissolved in physiological saline. All preparations were
at an appropriate concentration for the desired dose to be
administered in 0.1 ml per 10g body weight. All injections
were intraperitoneal (i.p.).
Animals
Pure strain NMRI mice were used from the Bradford Clin-
ical Oncology Unit inbred colony. Mice aged 6-8 weeks
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were used for therapy experiments and mice aged 4 weeks
were used for thymectomy. Nude mice of a Balb/C genetic
background purchased from Banting and Kingman (UK)
were used for the MAC and HT-29 study and nude mice
from the Istituto Nazionale per lo Studio e la Cura dei
tumori, Milan, were used for the COBA-P and COBA-M
tumours. NMRI mice were housed in cages in a air condi-
tioned room where regular alternate 12 h cycles of light and
darkness were maintained. Nude mice were housed in an
isolator in similar conditions. All animal procedures in the
UK were carried out under a Project Licence approved by
the Home Office, London. Thymectomies were carried out in
NMRI mice under Saffan (Glaxo, UK) anaesthesia and 7
days later thymectomised mice received whole body irradia-
tion (11 Gy) from a Newton Victor X-ray superficial therapy
set. Irradiated mice were reconstituted with 1 x 106 bone
marrow cells from normal NMRI mice.
Tumour systems
The development of several adenocarcinomas of the large
bowel in NMRI mice from primary tumours induced by
prolonged administration of 1,2-dimethylhydrazine has been
described previously (Double et al., 1975). For this study the
well differentiated slow growing MAC 26 tumour (Bibby et
al., 1989a) and the moderately to well differentiated cachexia
inducing MAC 16 tumour (Bibby et al., 1987a) were used.
HT-29 human colon cancer cells were received from the
Department of Pathology, University of Leeds and were
maintained as solid subcutaneous tumours in nude mice.
COBA-P is a moderately differentiated adenocarcinoma of
the Sigmoid colon which has been maintained in serial pas-
sage and COBA-M is a synchronous metastasis which has
retained its well differentiated appearance. All tumours were
transplanted subcutaneously into the flank.
Chemotherapy
Chemotherapy began when the tumours had reached a size
that could be accurately measured, and anti-tumour activity
was assessed either by tumour volume or tumour weight.
Tumours were established at the time of chemotherapy and
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Figure 1 Influence of FAA (200 mg kg- , day 0, day 7) on
growth of COBA-P (0, control 0, treated) and COBA-M (-,
control 0, treated) tumours in nude mice.
all tumours were ofcomparable size (- 4-5 mm in diameter).
The degree of tumour vasculature in MAC tumours im-
planted in all three hosts was comparable at the time of
treatment with MAC 26 tumours being relatively well vas-
cularised compared to MAC 16 tumours. HT-29 tumours
were poorly vascularised with a viable outer rim of tumour
cells and large central necrotic regions. The vascularity of
COBA-P and COBA-M tumours was not investigated.
Histology
The effects of treatment were assessed histologically by exam-
ination of haematoxylin and eosin stained paraffin wax sec-
tions.
Measurement ofdrug levels in plasma and tumours
Reagents: Spectroscopic grade ethanol (BDH Chemicals,
Poole, Dorset UK), p-dimethylaminobenzaldehyde (Sigma
Chemicals, Poole, Dorset UK) and triple distilled water were
used. Other agents were of analytical grade.
Sample collection
Blood samples from 3 HT-29 tumour bearing mice at each
time point were taken by cardiac puncture under ether anaes-
thesia, collected into heparinised tubes, centrifuged at 2000
r.p.m. and 4°C for 10 min and then separated plasma was
stored at - 20°C until analysis. The mice were killed by
cervical dislocation and rapidly dissected. Tumours were
immediately frozen in liquid nitrogen and stored at - 20°C.
Sample extraction andchromatography
FAA was extracted from fluid samples using solid phase
chromatography measured by the HPLC method described
by Double et al. (1986), and modified from Kerr et al. (1985).
FAA plus internal standard, dimethylaminobenzaldehyde
(100 LI at 100tLg ml-') were extracted from separated plasma
samples (50p1) using C18 Bond Elut cartridges that had
previously been primed using ethanol (1 ml) and washed with
distilled water (1 ml). Following further washing, FAA was
eluted in ethanol (500 ,ul) and injected into the HPLC.
Tumour samples were mixed with 0.1 M sodium acetate-
acetic acid buffer pH 4 (10% weight/volume) and homo-
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Figure 2 Influence of FAA on growth of HT-29 tumours in
nude mice (0, control U, 200mgkg-' A, 300mgkg-').ANTI-TUMOUR ACTIVITY OF NSC 347512 IN MICE 59
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Figure 3 Mean plasma concentration (± I s.d.) of FAA follow-
ing intraperitoneal administration of FAA (200 mg kg-') to nude
mice bearing HT-29 tumours.
Time (Hours)
Figure 4 Mean tumour concentration (± s.d.) of FAA follow-
ing intraperitoneal administration of FAA (200 mg kg-') to nude
mice bearing HT-29 tumours.
genised using an Ultra Turrax blender. Homogenates were
centrifuged at 2,500 r.p.m. at 4°C for 5 min. FAA plus inter-
nal standard (100 tl at 10 pg ml-') were extracted from the
supernatant (100ILI) as described above. Chromatography
was performed using a Waters HPLC system and com-
ponents were separated on a Lichrosorb RP-18 column and
detected using a Lambda Max model 480LC spectrophoto-
meter at 303 nm. An isocratic mobile phase consisting of
phosphoric acid (0.005 M, 62.5%), Methanol (12.5%), Ace-
tonitrile (12.5%) and Propan-2-ol (12.5%) was used. Stan-
dard curves were prepared by the addition of FAA to
buffered control mouse plasma (pH 4) and plotting a ratio of
peak areas of FAA to the internal standard against drug
concentration. Peaks were traced and integrated with an
Isaac Model 42A data module (Syborg Corporation, USA)
using an Apple IIE Computer (Apple Computer Inc., USA)
and Appligration II Software (Dynamic Solutions Corpora-
tion, USA). The assay was sensitive to drug concentrations
down to 10ng ml-' and recovery was greater than 90%.
Pharmacokinetic analysis
For HT-29 tumours in nude mice the area under the concen-
tration versus time curves (AUC) was calculated for plasma
and tumour samples using the trapezoid rule.
Results
FAA treatment at maximum tolerated dose (MTD) on day 0
and day 7 has no influence on the growth of COBA-P,
COBA-M and HT-29 tumours growing in nude mice (Figures
1 and 2) and histological examination revealed no additional
necrosis in the treated tumours.
Plasma profiles of FAA in nude mice bearing HT-29,
following i.p. administration of 200 mg kg-' are presented in
Figure 3. Peak levels of 380 sg mlP' are achieved at 30 min
after treatment. FAA levels in HT-29 tumours are presented
in Figure 4. AUC (0-24 h) for FAA was 1,336 1tg h ml-' and
517 ig h g-' for plasma and tumour respectively. A repeat
experiment gave a plasma AUC = 1,546lag h ml-'.
The influence of FAA treatment in MAC tumours is pre-
sented in Figures 5 and 6. The growth rate of MAC tumours
in all three hosts was similar with the exception of MAC 16
tumours in NMRI mice which have a slower growth rate
than tumours in nude or thymectomised mice. (This may be
an artefact as growth rates of MAC 16 are more variable
because of the large areas of necrosis occurring in this
tumour line). A dose of 200 mg kg-' on day 0 and day 7 to
MAC 26 tumours causes a growth delay of greater than 30
days in normal NMRI mice and two out of ten mice have
complete remission (Figure Sa). However this effect is lost in
both nude hosts (Figure Sb) and thymectomised NMRI hosts
(Figure 5c). MAC 26 responses to cylcophosphamide, SFU
and TCNU are similar in NMRI and nude hosts (Table I).
There were no significant differences in peak plasma levels in
normal NMRI tumour bearers (333 ytgml-') and thymecto-
mised NMRI tumour bearers (343 jig ml-'). Similar observa-
tions were made with the MAC 16 tumours. Eight out of ten
tumours in normal NMRI mice were cured (Figure 6a)
whereas no significant growth delays were observed in either
nude (Figure 6b) or thymectomised NMRI mice (Figure 6c).
This tumour is resistant to a large range of anti-cancer drugs
and there is no measurable activity with cyclophosphamide,
SFU or TCNU in either NMRI or nude hosts. The MAC 16
tumour is highly necrotic and on histological examination
there were no clear differences between treated and untreated
tumours. However the untreated MAC 26 tumours does not
normally become necrotic (Figure 7) and histological exam-
ination of treated tumours from all three hosts demonstrated
a similar degree of haemorrhagic necrosis (Figure 8) even
though there were no observable growth delays in both nude
and thymectomised hosts. Tolerance of FAA was influenced
by the tumour type with the MTD in MAC 26 and MAC 16
tumour bearing mice being 300 and 200mgkg-' i.p. respec-60 M.C. BIBBY et al.
tively. The influence of the host on FAA tolerance was
minimal.
Discussion
There can be little doubt that FAA has a complex mech-
anism of action against murine tumours that is mediated via
an indirect rather than a direct cytotoxic event. Proposed
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mechanisms include its action as a biological response mod-
ifier through the activation of NK cells and macrophages
(Ching & Baguley, 1987; Hornung et al., 1988; Ching &
Baguley, 1988), interference with tumour endothelium result-
ing in the collapse of the vascular supply (Bibby et al., 1989a;
Zwi et al., 1989), and metabolism to a more cytotoxic species
in vivo (Chabot et al., 1989). The results of this study clearly
demonstrate that the anti-tumour activity of FAA is depen-
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Figure 5 Influence of FAA (200 mg kg-', day 0, day 7) on the
growth of MAC 26 tumours in a, normal NMRI mice, b, nude
mice, c, thymectomised NMRI mice (0, control *, treated).
Figure 6 Influence of FAA (200 mg kg-' day 0, day 7) on the
growth of MAC 16 tumours in a, normal NMRI mice, b, nude
mice, c, thymectomised NMRI mice (0, control *, treated).
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Table I Comparative effects of four anti-cancer agents against MAC 26 tumours
growing in syngeneic and nude hosts
Percentage tumour volume inhibition*
Cyclophosphamide FAA SFU TCNU
Host (200 mgkg-') (200 mgkg-') (120 mgkg-') (20 mgkg-')
NMRI 31.0 86.0 55.2 54.5
Nude 27.5 0 44.8 58.6
*Calculated from relative tumour volume curves at day 14 following single
intraperitoneal doses at day 0. Data represent mean values from two independent
experiments in each case.
Figure 7 Normal appearance of MAC 26 growing in nude hosts
(Haematoxylin and Eosin, bar = 50jSLm).
Figure 8 Histological appearance of a MAC 26 tumour from a
nude mouse following treatment with FAA (200 mg kg-' x 2)
(Haematoxylin and Eosin, bar = 80gm).
dent upon the immunological status of the host. In normal
NMRI mice, both MAC 16 and MAC 26 tumours grown
subcutaneously respond to FAA with haemorrhagic necrosis
seen within 4 h following drug administration (Bibby et al.,
1987b; Bibby et al., 1988a). When MAC tumours are grown
subcutaneously in nude mice or thymectomised NMRI mice
however, the anti-tumour effects of FAA are significantly
reduced even though haemorrhagic necrosis was still ob-
served. The extent to which haemorrhagic necrosis occurred
in MAC tumours was comparable in all three hosts. No
significant anti-tumour effects were seen in the three human
tumour xenografts grown in nude mice. There was also no
evidence of haemorrhagic necrosis in these tumours and the
reasons for this require investigation. Pharmacokinetic stud-
ies suggest that the poor response of HT-29 xenografts to
FAA is unlikely to be the result of poor drug bioavailability.
Tumour levels of FAA in HT-29 xenografts (AUC = 517 yg
h g-1) are comparable with those achieved in the highly
responsive MAC 16 tumour (AUC = 500 gsg h g-') following
the i.p. administration of FAA (Bibby et al., 1988a). Further-
more, preliminary pharmacokinetic studies also suggest that
the lack of activity of FAA against MAC 26 in thymec-
tomised hosts is not the result of poor drug bioavailablity as
peak plasma levels of FAA are equivalent to those achieved
in MAC 26 tumours in normal NMRI mice (343 and
333 g ml-' respectively) (Phillips et al., 1990).
The results of this study demonstrate that the host immune
response is an important component in the mechanism of
action of FAA. It may also be true to say however, that the
activity of FAA may depend upon the immunogenicity of the
tumour lines employed, although the activity reported by Hill
et al. (1989) in non-immunogenic tumours (Hewitt et al.,
1976) suggests this is unlikely. The high transplantation take
rates and relative insensitivities of MAC tumours to standard
cytotoxic drugs (Bibby et al., 1988a, Double et al., 1975)
suggest that MAC tumours are not strongly immunogenic.
There are no significant differences in the response rates of
MAC tumours to standard anti-cancer drugs (nitrosoureas,
cyclophosphamide, 5-fluorouracil) in NMRI and nude mice
hosts. Sequential excision of MAC 15A tumours and assess-
ment of clonogenic cell kill in vitro at various time intervals
following FAA administration indicated that major cell kill
occurred between 4 and 6 h after treatment in syngeneic
hosts whereas limited cell kill was observed in tumours in
nude mice (Phillips et al., 1990).
The exact mechanism by which FAA interacts with the
immune system remains unclear although several studies have
shown that FAA is capable ofactivating NK cells in vivo and
macrophages in vitro (Ching & Baguley, 1987; Hornung et
al., 1988; Ching & Baguley, 1988). In this respect, it is of
interest to note that the characteristic features of FAA
induced anti-tumour activity (i.e. the requirement for estab-
lished tumours, rapid appearance of haemorrhagic necrosis,
site dependent responses and the necessity for an immuno-
competent host) bear a striking resemblance to those re-
ported for endotoxin (Parr et al., 1973). The process by
which endotoxin induces anti-tumour effects is also indirect,
depending upon a complex interaction of several host factors
rather than direct action on tumour cells themselves. Interest-
ingly haemorrhagic necrosis involving coagulation was found
to be essential but not in itself sufficient to account for the
dramatic anti-tumour effects (Parr et al., 1973). The demon-
stration that MAC tumours grown in thymectomised NMRI
mice also undergo haemorrhagic necrosis without signifi-
cantly influencing the growth of the tumour closely mimics
that seen with endotoxin. Clearly therefore, the occurrences
of haemorrhagic necrosis, whilst it is an essential feature of
FAA induced responses, is not the only mechanism involved.
For significant anti-tumour activity to occur some additional
component(s) of the immune system appears necessary. A
recent study by Pratesi et al. (unpublished) has shown that
FAA is active against colon 26 tumours in euthymic but not
athymic mice and has also identified a role for L3T4 T
lymphocytes in FAA induced regression of colon 26 tumours
in Balb/c mice.
Haemorrhagic necrosis has not been detected clinically, but
it is possible that FAA might induce haemorrhagic necrosis
in human tumours without it being detected as a recognisable
anti-tumour response. If haemorrhagic necrosis does occur in
patients, these vascular effects may be compounded by com-
bination studies with standard anti-cancer drugs. Studies to
determine whether or not haemorrhagic necrosis occurs in
other human tumour xenografts and the effects of combina-
tion chemotherapy are currently under way.
In view of the similarities between the anti-tumour effects
of FAA and endotoxin, it is reasonable to assume that both
compounds induce cytotoxic events via a common mech-62 M.C. BIBBYet al.
anism. It is generally accepted that the anti-tumour effects of
endotoxins are mediated through the formation of tumour
necrosis factor (TNF) secreted primarily by activated macro-
phages (Old, 1988). The involvement of TNF in the anti-
tumour activity of FAA has been inferred in a recent study
where the pre-treatment of tumour bearing mice with an
anti-serum to recombinant murine TNF a prevents the vas-
cular collapse associated with FAA induced cytotoxicity
(Mahadevan et al., 1990). It seems likely therefore that TNF
secretion within the solid tumour mass may play a major role
in the anti-tumour activity of FAA although other cytokines
secreted by other components of the immune system cannot
be ruled out at this stage.
In conclusion, the results of this study clearly demonstrate
the important role played by the host's immune system in the
mechanism of action of FAA. Vascular effects resulting in
haemorrhagic necrosis alone are not sufficient to account for
the dramatic anti-tumour activity reported and other factors
are required. Studies to determine the essential components
involved are currently in progress.
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